Kura Oncology, Inc. (KURA)
$10.60+0.76%Close
SELLBEAR · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $941M
- Beta
- 0.38
- P/E (TTM)
- -3.12
- Short % float
- 16.77%
- Days to cover
- 7.7
- SI change
- -2.7%
- 1W
- -0.47%
- 1M
- -8.38%
- vs SPY 1W
- -1.63%
- vs SPY 1M
- -11.38%
Industry peers
FMP comparable companies · ranked by market cap
- HCMBUYHUTCHMED (China) Limited$2.5BRECOVERYQ 5$14.10+3.15%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35+0.63%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.2BBEARQ -9$11.65+3.46%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.99+0.53%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-0.33%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.94-0.15%
- RIGLBUYRigel Pharmaceuticals, Inc.$908MBULLQ 9$49.08+0.74%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38+3.33%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KURA?
- LOPJLB’s latest quantitative signal on Kura Oncology, Inc. (KURA) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is KURA in?
- Kura Oncology, Inc. (KURA) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Kura Oncology, Inc. (KURA) do?
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted the…